U.S. Influenza Market Size, Share, Competition Landscape, Manufacturers Analysis And Future Opportunity 2021-2027 | Says PBI Analyst

Precision Business Insights published a research report on "U.S. Influenza Market by Drug Class (Anti-viral drugs, Vaccines), Route of Administration (Oral, Parenteral, Others), Distribution Channel (Hospital pharmacies, Retail pharmacies, Others) - Global/Region/Country Forecast to 2027"

Flu is the colloquial name for influenza, which is caused by the influenza virus. The three kinds of influenza virus, Type A, Type C, and Type B are distinguished by their surface proteins, Hemagglutinin (HA) and Neuraminidase (NA). The U.S. influenza market size was valued at USD 109.1 million in the year 2018 and is predicted to increase at a CAGR of 5.3% during the projected timeframe. As influenza is a communicable disease, it is easily transmitted in public areas by sick individuals, who frequently act as disease carriers. The market is expected to grow as the disease's prevalence rises in the United States. For instance, as per the Centers for Disease Control and Prevention (CDC), influenza cases began to climb in November, peaked in January and February, and remained high until the end of March. The percentage of those infected with influenza was projected to be 7.6%, the highest since 2009.

View Detailed Report Description at https://precisionbusinessinsights.com/market-reports/u-s-influenza-market/

Increased government activities aimed at facilitating diagnosis have made it easier to get OTC tests that are user-friendly and help in timely diagnosis. For example, the Biomedical Advanced Research and Development Authority (BARDA), which is a significant part of the United States Department of Health and Human Services, released a report in 2018 stating that the U.S. The Department of Health and Human Services signed a partnership with Diassess Inc. and Cue Health, Inc. to produce influenza testing kits. These over-the-counter devices are only designed for use in home care settings, allowing worried patients to test for influenza. Growing demand is also expected to be fueled by the growing elderly population. Because the elderly population's immune systems are weakened, they are more sensitive to disease and so have a higher chance of acquiring influenza. Children, pregnant women, immunocompromised patients with a variety of chronic illnesses, and healthcare professionals are among those at greatest risk of getting the flu virus. In April 2019, the Centers for Disease Control and Prevention (CDC) reported 186 influenza-related pediatric fatalities in the United States. Furthermore, the market's growth is expected to be hampered by the uniformity of results and the high cost of diagnostic instruments.

The Global U.S. Influenza Market is fragmented on the basis of Test Type, which is further divided into RT-PCR, RIDT, Cell Culture, Others. On the basis of End Use, the U.S. Influenza Market is segregated into Laboratories, Hospital, and POCT. On the basis of test type, RDIT is expected to hold the major market share in 2018 as they are easily accessible and are user friendly enabling current diagnosis.
In order to enhance the availability of influenza vaccinations, government entities in the United States are focused on cooperation. Furthermore, the Advisory Committee on Immunization Practices' recommendation to obtain influenza vaccine in order to lessen the disease's significant yearly health impact is projected to boost the market's growth over the coming years.

Request sample report at https://precisionbusinessinsights.com/request-sample?product_id=15946

There are several industry players working in the u.s. influenza market, which include AstraZeneca (U.K.), F. Hoffmann-La Roche (Switzerland), GlaxoSmithKline plc (U.K.), Novartis AG (Switzerland), Sanofi (France), Seqirus (U.K.), Protein Sciences Corporation (U.S.), Emergent Biosolutions (U.S.), BioCryst Pharmaceuticals.Inc (U.S.)., Alvogen (South Korea), Medimmune Inc. (U.S.), DynPort Vaccine Company, LLC. (U.S.), and Abbott Laboratories (U.S.) to name a few.

Contact:
Mr. Satya
Precision Business InsightsTM | Toll Free: +1 866 598 1553
Email: sales@precisionbusinessinsights.com
Kemp House, 152 – 160 City Road, London EC1V 2NX
Web: https://precisionbusinessinsights.com/ | D U N S® Number: 852781747

About Precision Business Insights:
We are a market research company that strives to provide the highest quality market research insights. Our diverse market research experts are enthusiastic about market research and therefore produce high-quality research reports. We have over 500 clients with whom we have a good business partnership and capacity to provide in-depth research analysis for more than 30 countries. In addition to deliver more than 150 custom solutions, we already have accounts with the top five medical device manufacturers.

Precision Business Insights offers a variety of cost-effective and customized research services to meet research requirements. We are a leading research service provider because of our extensive database built by our experts and the services we provide.

This release was published on openPR.